Sign in
Not yet recruitingNo phase

Multi-center Study of Three-Dimensional Transesophageal Echocardiography in Patients With Secondary Mitral Regurgitation

Key facts

Who runs it
First Hospital of China Medical University
Where
China, Hong Kong, and Taiwan92 sites in 3 countriesChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
2,400 people, planned
Started
1 Nov 2026
Expected to end
30 Nov 2028
Type of study
Observational, 2 groups
Treatments tested
  • Transthoracic and Three-Dimensional Transesophageal Echocardiography
Record updated
5 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Atrial Secondary Mitral Regurgitation Group:
  • Age 18 years or older
  • At least mild atrial secondary mitral regurgitation, meeting all of the following criteria:; Structurally normal mitral valve without primary mitral valve disease; Left ventricular ejection fraction ≥50%, without regional wall motion abnormalities or mitral leaflet tethering; Normal or mildly enlarged left ventricle, meeting either of the following sex-specific criteria:; Left ventricular end-diastolic diameter <56 mm in women or <63 mm in men; Left ventricular end-diastolic volume index <71 mL/m² in women or <79 mL/m² in men; Mitral annular dilatation, defined as an anteroposterior diameter >35 mm, together with left atrial enlargement meeting either of the following criteria:; Left atrial volume index >34 mL/m²; Left atrial anteroposterior diameter >37 mm in women or >39 mm in men
  • Undergoing both transthoracic and transesophageal echocardiography, with standardized images retained; Control Group:
  • Age 18 years or older
  • Undergoing transesophageal echocardiography for clinical indications, such as suspected patent foramen ovale or infective endocarditis
  • Transthoracic echocardiography showing no significant abnormalities in cardiac structure or function, with less than mild regurgitation of all cardiac valves; All participants must meet the inclusion criteria for their respective group and provide written informed consent

Who cannot take part

  • Previous cardiac valve surgery or catheter-based valve intervention
  • Primary mitral regurgitation caused by organic mitral valve disease, including degenerative changes, rheumatic involvement, congenital mitral valve abnormalities, or vegetations
  • Moderate or greater aortic valve disease
  • Congenital heart disease
  • The following exclusion criteria apply to both groups:
  • Inadequate three-dimensional transesophageal echocardiographic image quality that precludes reliable assessment of mitral valve structure and motion
  • Contraindications to, or inability to tolerate, transesophageal echocardiography
  • Refusal to provide written informed consent

This trial has no sites in United States.

It has sites in 3 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

Three-dimensional transesophageal echocardiography (3D-TEE) enables detailed assessment of mitral valve anatomy, annular geometry, and regurgitation. This prospective multicenter observational study will evaluate atrial secondary mitral regurgitation (A-SMR) using 3D-TEE combined with transthoracic echocardiography. The study aims to characterize regurgitation severity and associated factors and compare mitral valve structure and left ventricular function between patients and controls. It will also investigate echocardiographic predictors of clinical outcomes during follow-up.

The 2 groups in the trial

  • Atrial Secondary Mitral Regurgitation Group

    This group will include 1,600 adults aged 18 years or older with at least mild atrial secondary mitral regurgitation who meet the eligibility criteria. Participants will undergo transthoracic and three-dimensional transesophageal echocardiography to assess mitral valve structure, regurgitation severity, and cardiac function. Transesophageal echocardiography will be performed for clinical indications, without additional transesophageal examinations solely for research. Clinical follow-up will be conducted every three months.

    Treatment: Transthoracic and Three-Dimensional Transesophageal Echocardiography

  • Control Group

    This group will include 800 adults aged 18 years or older undergoing clinically indicated transesophageal echocardiography. Transthoracic echocardiography must show no substantial structural or functional cardiac abnormalities, with less than mild regurgitation of all cardiac valves. Participants must meet the control-group eligibility criteria and have none of the exclusion criteria. Transthoracic and three-dimensional transesophageal echocardiographic images will be analyzed for comparison with the atrial secondary mitral regurgitation group.

    Treatment: Transthoracic and Three-Dimensional Transesophageal Echocardiography

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Secondary Mitral Regurgitation Assessment Using Three-dimensional Transesophageal Echocardiography: A Multicenter Clinical Study
Record updated
5 November 2026